Related references
Note: Only part of the references are listed.Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab′)2-A Phase I Study
Hakan Andersson et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival
Angele L. Oei et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab′)2
Jorgen Elgqvist et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Fractionated radio immunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab′)2:: therapeutic efficacy and myelotoxicity
Jorgen Elgqvist et al.
NUCLEAR MEDICINE AND BIOLOGY (2006)
Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission
RH Verheijen et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Radioimmunotherapy in advanced ovarian cancer:: is there a role for pre-targeting with 90Y-biotin?
C Grana et al.
GYNECOLOGIC ONCOLOGY (2004)
Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: Effect of the radionuclide
ML Janssen et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2003)
Intraperitoneal radioimmunochemotherapy of ovarian cancer: A phase I study
RF Meredith et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2001)
Dry-distillation of astatine-211 from irradiated bismuth targets:: a time-saving procedure with high recovery yields
S Lindegren et al.
APPLIED RADIATION AND ISOTOPES (2001)
High-efficiency astatination of antibodies using N-iodosuccinimide as the oxidising agent in labelling of N-succinimidyl 3-(trimethylstannyl)benzoate
S Lindegren et al.
NUCLEAR MEDICINE AND BIOLOGY (2001)
Intraperitoneal radioimmunotherapy with human monoclonal IGM in nude mice with peritoneal carcinomatosis
PE Borchardt et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2000)
Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy
AA Epenetos et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2000)
Share Paper
